Back to Results
First PageMeta Content
Melanoma / Organochlorides / Sulfonamides / Vemurafenib / BRAF / Protein kinase inhibitor / Pharmaceutical Benefits Scheme / Metastasis / Melbourne Sports and Aquatic Centre / Medicine / Healthcare in Australia / Health


Public Summary Document Application No.1207 – BRAF V600 mutation testing associated with access to PBS-listed dabrafenib
Add to Reading List

Document Date: 2014-11-06 23:50:11

Open Document

File Size: 78,32 KB

Share Result on Facebook

Company

IVDs / MSAC / GlaxoSmithKline Australia Pty Ltd / /

Country

Australia / /

Currency

USD / /

IndustryTerm

medicine technologies / health services / agreed clinical protocols / clinical management / co-dependent health technologies / health technology assessments / diagnostic medical devices / /

MarketIndex

MBS / /

MedicalCondition

IV (metastatic) melanoma / IV metastatic cutaneous melanoma / metastasis / IV melanoma / tumour / BRAF V600 positive melanoma / melanoma / positive metastatic melanoma / melanoma tumours / BRAF mutant tumours / metastatic melanoma / /

MedicalTreatment

clinical protocols / chemotherapy / /

Organization

National Health and Medical Research Council / National Pathology Accreditation Advisory Committee / Pharmaceutical Benefits Advisory Committee / World Health Organization / International Organisation for Standardisation / Therapeutic Goods Administration / Australian Health Ministers’ Advisory Council / National Association of Testing Authorities / Medicare / /

Position

Governor / Minister / Executive / consultant physician / /

Product

dacarbazine / /

Technology

agreed clinical protocols / chemotherapy / medicine technologies / co-dependent health technologies / /

URL

www.msac.gov.au / /

SocialTag